ÂÜÀòÂÒÂ×

Keith Wilson has worked in the biotechnology industry since 1997. From 1997 to 2002, they held the position of Senior Scientist at Eos Biotechnology, before being promoted to Director of Computational Genomics. In 2003, they joined PDL BioPharma as Director of Computational Biology and Genomics, where they were responsible for early pipeline strategies and portfolio management. In 2009, they moved to Facet Biotech as Senior Director of Research, where they co-led the research department through a corporate transition and led internal scientific and business reviews of the pipeline portfolio and strategy. In 2010, they joined Abbott Laboratories as Director of Discovery, where they were a member of the site leadership team and responsible for department leadership of 37 individuals. In 2013, they joined AbbVie as Director of Discovery and was a member of the site leadership team. In 2014, they joined Oxford BioTherapeutics as Chief Scientific Officer, where they led strategic review and directional change of the company, focused the company's proprietary platform toward new areas of T cell biology, and was responsible for all scientific operations across the company. In 2017, they founded Nalo Therapeutics, Inc., where they served as Founder, President, and Chief Scientific Officer. In 2018, they co-founded Trilo Therapeutics and served as chair of the Scientific Advisory Board.

Keith Wilson completed a Post doctoral fellowship at Stanford University School of Medicine from 1992 to 1997. Prior to that, they earned a Ph.D. in Biochemistry and Molecular Biology from Oregon Health & Science University from 1988 to 1992. Before that, they earned a BS in Biochemistry from The University of New Mexico School of Medicine from 1986 to 1988.